Stuttgart
24.08.26 | 21:55
25,140 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,000 | 25,760 | 24.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | XVIVO erhält CE-Zertifikate für bahnbrechende Technologie zur Herzkonservierung | 1.465 | news aktuell | Göteborg/Berlin (ots) - - Die CE-Zertifizierungen ermöglichen den breiteren Einsatz der innovativen XVIVO-Technologie und verbessert den Zugang zu Herztransplantationen in Europa. XVIVO gibt die CE-Zertifizierungen... ► Artikel lesen | |
| 11.08. | Xvivo Perfusion AB: XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe | 249 | GlobeNewswire (Europe) | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| 03.08. | XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport | 345 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval... ► Artikel lesen | |
| 14.07. | Xvivo Perfusion AB (publ) reports Q2 results | 3 | Seeking Alpha | ||
| 14.07. | Xvivo Perfusion AB Q2 Profit Rises | 3 | RTTNews | ||
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 14.07. | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | 1 | Investing.com Deutsch | ||
| 14.07. | XVIVO Perfusion AB: Interim Report January - June 2026 | 458 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 09.07. | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 356 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 454 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 399 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 323 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M | 1 | Seeking Alpha | ||
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 216 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 232 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 513 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto | 448 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, preliminary one-year follow-up data from the US PRESERVE trial of XVIVO's investigational... ► Artikel lesen | |
| 22.04. | Late-Breaking Data from PRESERVE Trial Evaluates XVIVO's HOPE Preservation Approach in Heart Transplantation | 469 | Business Wire | Preliminary results suggest potential to support extended preservation time and donor heart utilization XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking... ► Artikel lesen | |
| 17.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2026 | 367 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2026.... ► Artikel lesen | |
| 16.04. | XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal | 354 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter... ► Artikel lesen | |
| 02.04. | Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M | 4 | Seeking Alpha |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 32,300 | -0,55 % | BERENBERG stuft CARL ZEISS MEDITEC AG auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 28 Euro auf "Hold" belassen. Der neue Chef der Jenaer müsse einiges auf dem Schirm... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,180 | -3,44 % | Eckert & Ziegler: Warum der höhere Gewinn zählt | ||
| INTUITIVE SURGICAL | 322,00 | +0,48 % | Intuitive Surgical: Exzellentes Geschäftsmodell, aber ist die Aktie jetzt zu teuer? | Intuitive Surgical gilt als Qualitätsunternehmen mit dominierender Marktstellung in der roboterassistierten Chirurgie, doch die aktuelle Bewertung der Aktie erscheint angesichts der jüngsten Kennzahlen... ► Artikel lesen | |
| RHOEN-KLINIKUM | 14,700 | 0,00 % | Asklepios Kliniken will Altaktionäre der RHÖN-KLINIKUM AG abfinden | Die Asklepios Kliniken GmbH & Co. KGaA will Altaktionäre der RHÖN-KLINIKUM AG abfinden: Hierfür hat der Asklepios-Klinikkonzern als Mehrheitsaktionär der RHÖN-KLINIKUM sein Verlangen auf Durchführung... ► Artikel lesen | |
| BICO GROUP | 1,816 | +0,55 % | BICO Group AB: Publication of BICO Group AB: Interim Report Q2 2026 | Improved profitability and AI advancements
"In the quarter we had a continued solid momentum with growth in our bench top instruments and consumables businesses, while still experiencing challenges... ► Artikel lesen | |
| M1 KLINIKEN | 18,220 | +0,11 % | Dividendenbekanntmachungen (09.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,63 USD 1,4275 EUR ALIMENTATION COUCHE-TARD INC CA01626P1484 0,215 CAD 0,1328 EUR ANPARIO PLC GB00B3NWT178 0... ► Artikel lesen | |
| BAXTER | 22,460 | -1,14 % | Baxter erhöht maximales Rückkaufvolumen für Anleihen auf 600 Millionen US-Dollar | ||
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 4,047 | -3,01 % | Nomura Cuts JD HEALTH TP to HKD60; Regulatory Headwinds Mainly Concentrated in Nutrition Products Segment | ||
| COOPER COMPANIES | 65,30 | +0,45 % | Cooper Companies Posts Q2 Loss Hurt By One-Time Litigation Charge, Revenue Rises 8% | WASHINGTON (dpa-AFX) - Cooper Companies, Inc. (COO) on Thursday posted a net loss due to a substantial litigation-related charge tied to a 2023 product recall. However, the company reported... ► Artikel lesen | |
| LIFEWARD | 7,290 | 0,00 % | H.C. Wainwright reiterates Lifeward stock rating on revenue growth | ||
| BONESUPPORT | 19,790 | -0,05 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen | |
| ONWARD MEDICAL | 2,280 | -0,65 % | ONWARD Medical NV: ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones | EINDHOVEN, the Netherlands, May 26, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD - US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 2,540 | -0,78 % | Community Health Systems forecasts 2026 adjusted EBITDA of $1.3B-$1.375B amid softer elective surgeries and higher uninsured volumes | ||
| RAMSAY HEALTH CARE | 26,800 | -1,47 % | RAMSAY SANTE: Press Release - Refinancing new steps forward | PRESS RELEASE Paris, 22nd July 2026 New steps in connection with Ramsay Santé contemplated free-float expansion: Ramsay Santé successfully completes its senior debt refinancing and convenes a Capital... ► Artikel lesen |
Das Unternehmen XVIVO PERFUSION AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 25,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.